Celltrion Inc.
Scope
Date
~
-
Bio & Pharma
Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey
South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...
Apr 21, 2023 (Gmt+09:00)
-
Private equity
MBK Partners co-founder tops 50 richest S.Koreans: Forbes
Michael ByungJu Kim, co-founder and partner at private equity firm MBK Partners, has topped the ranking of the 50 richest South Koreans by net worth...
Apr 18, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Korea's Celltrion Healthcare launches Vegzelma in US
South Korea's Celltrion Healthcare Co. on Monday said it launched on the US market Vegzelma, a biosimilar of Bevacizumab, a medication for colorecta...
Apr 17, 2023 (Gmt+09:00)
-
Shareholder activism
KCGI’s ascent to intensify family feud over DB control; DB stocks rally
A sibling feud over management control of DB Group is expected to intensify following the ascent of South Korean activist fund Korea Corporate Gover...
Apr 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Biosimilar giant Celltrion to transform into drug developer
South Korean biosimilar giant Celltrion Group aims to transform into a drug developer by generating 40% of sales from new medicines by 2030 as it is...
Mar 29, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion founder returns to management with M&A pledge
South Korean biosimilar giant Celltrion Group’s founder Seo Jung-jin has returned to management two years after his departure, pledging to mer...
Mar 28, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion eyes Baxter's arm as it gears up for M&As
Celltrion Inc., South Korea’s largest biosimilar maker, said on Tuesday it has studied a possible acquisition of the biopharma solutions unit ...
Mar 21, 2023 (Gmt+09:00)
-
Supply chain
Samsung SDS acquires Korea’s No. 1 procurement SCM company
Samsung SDS Co., the information technology service unit of South Korea's Samsung Group, has acquired a 33.39% stake in Emro Inc., Korea's top suppl...
Mar 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Genuv sign agreement for antibody joint R&D
South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday a joint research and development agreement with Genuv, Inc., a domestic drug...
Mar 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion ex-Chairman Seo set to return to management; group stocks rally
South Korea’s biosimilar giant Celltrion Group’s founder and Honorary Chairman Seo Jung-jin is readying to return to management just two...
Mar 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion teams up with bio venture to develop new anti-cancer drug
South Korea's biopharmaceutical company Celltrion Inc. will develop an anti-cancer drug that combines oncolytic virus technology with biosimilars un...
Feb 28, 2023 (Gmt+09:00)
-
Bio & Pharma
Brazil approves Celltrion Pharm’s syringe facility
Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for it...
Feb 20, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Truxima shows safety, efficacy in post-marketing study
South Korean biopharmaceutical company Celltrion Inc. reported on Wednesday that its biosimilar drug Truxima (rituximab), a generic version of Roche...
Feb 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches anti-cancer biosimilar Vegzelma in Japan
Celltrion Healthcare Co. Ltd. said on Thursday that it launched Vegzelma, a biosimilar to the anti-cancer drug Avastin (active ingredient: bevacizum...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion increases its stake in British ADC developer Iksuda
Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...
Jan 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Inc. eyes significant growth in bio business from 2024
SAN FRANCISCO – SK Inc., the investment and holding company of South Korea’s SK Group, expects significant growth in its biopharma...
Jan 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year
South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to tre...
Jan 11, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion develops oral antibody drug with US bio company
South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...
Jan 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion acquires approval to sell Vegzelma in Canada
South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma...
Jan 05, 2023 (Gmt+09:00)
-
Corporate investment
S.Korea Inc. ramps up cash reserves amid economic woes
South Korean companies are rushing to raise cash from the beginning of the new year amid growing concerns over a global economic downturn and market...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
ESG
SK Inc. gets highest AAA grade in MSCI's ESG rating
SK Inc., SK Group's investment arm, won the highest AAA ratings from both Morgan Stanley Capital International (MSCI) and the Dow Jones Sustainabili...
Dec 27, 2022 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Executive reshuffles
Hyundai becomes younger with 1 in 3 new executives in their 40s
South Korea’s Hyundai Motor Group, which owns Hyundai Motor Co. and Kia Corp., has carried out a year-end mid-tier executive reshuffle marked ...
Dec 20, 2022 (Gmt+09:00)
-
ESG
SK Inc. bulks up green investments to achieve net zero by 2035
SK Inc., the investment arm of South Korea’s second-largest conglomerate SK Group, is taking preemptive steps to expand its eco-friendly busin...
Dec 01, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion to seek FDA approval for sale of Remsima SC by year-end
Celltrion Inc. said it has confirmed the effectiveness and safety of Remsima SC in its third-phase global clinical trials, conducted on 438 patients...
Nov 28, 2022 (Gmt+09:00)
-
Korean chipmakers
Korea's SK Inc. revs up power semiconductor value chains via M&As
SK Inc., the investment arm of South Korea’s second-largest conglomerate SK Group, is ramping up its value chain of third-generation semicondu...
Nov 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...
Nov 18, 2022 (Gmt+09:00)